Molecule Details
| InChIKey | GHYOCDFICYLMRF-UTIIJYGPSA-N |
|---|---|
| Compound Name | Zetomipzomib |
| Canonical SMILES | COc1ccc([C@@H](O)[C@H](NC(=O)[C@H](C)NC(=O)CN2CCOCC2)C(=O)N[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 6 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 6.54 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB16070 |
|---|---|
| Drug Name | Zetomipzomib |
| CAS Number | 1629677-75-3 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis). |
Categories: Oxazines
Cross-references: BindingDB: 50526811 CHEMBL4297468 ChemSpider: 78434307
Target Activities (6)
| Target | Gene | Organism | Category | Pfam | pChEMBL | Type | Source |
|---|---|---|---|---|---|---|---|
| P28062 | PSMB8 | Homo sapiens | Human | PF00227 | 7.4 | IC50 | ChEMBL;BindingDB |
| P28065 | PSMB9 | Homo sapiens | Human | PF00227 | 6.9 | IC50 | ChEMBL;BindingDB |
| P20618 | PSMB1 | Homo sapiens | Human | PF00227 | 6.4 | IC50 | ChEMBL;BindingDB |
| P49721 | PSMB2 | Homo sapiens | Human | PF00227 | 6.2 | IC50 | ChEMBL;BindingDB |
| P40306 | PSMB10 | Homo sapiens | Human | PF12465 PF00227 | 6.2 | IC50 | ChEMBL;BindingDB |
| P28074 | PSMB5 | Homo sapiens | Human | PF00227 | 6.2 | IC50 | ChEMBL;BindingDB |